期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 20, 期 12, 页码 3265-3286出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v20.i12.3265
关键词
Gastric cancer; Biomarker; Liquid biopsy; Circulating tumor cells; Cell-free nucleic acids; MicroRNA
资金
- Grants-in-Aid for Scientific Research [23501299] Funding Source: KAKEN
To improve the clinical outcomes of cancer patients, early detection and accurate monitoring of diseases are necessary. Numerous genetic and epigenetic alterations contribute to oncogenesis and cancer progression, and analyses of these changes have been increasingly utilized for diagnostic, prognostic and therapeutic purposes in malignant diseases including gastric cancer (GC). Surgical and/or biopsy specimens are generally used to understand the tumor-associated alterations; however, those approaches cannot always be performed because of their invasive characteristics and may fail to reflect current tumor dynamics and drug sensitivities, which may change during the therapeutic process. Therefore, the importance of developing a non-invasive biomarker with the ability to monitor real-time tumor dynamics should be emphasized. This concept, so called liquid biopsy, would provide an ideal therapeutic strategy for an individual cancer patient and would facilitate the development of tailor- made cancer management programs. In the blood of cancer patients, the presence and potent utilities of circulating tumor cells (CTCs) and cell-free nucleic acids ( cfNAs) such as DNA, mRNA and microRNA have been recognized, and their clinical relevance is attracting considerable attention. In this review, we discuss recent developments in this research field as well as the relevance and future perspectives of CTCs and cfNAs in cancer patients, especially focusing on GC. (c) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据